Q: Why is CVS down after their earnings beat ?
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Is there a "reason " behind SIS announcing its preliminary and un audited year end and last quarter financial results suddenly , which it had never done in the past ? The figures were not that bad when compared to street estmates, though EBITDA was marginally lower . Is something "brewing " for SIS which an ordinary investor is unaware?
Q: What are your thoughts on SIS's premature earnings release with disappointing EBITDA miss and lowered guidance? Also they pointed to less acquisitions and more focusing on getting the house in order. Obviously not good to hear they are struggling in Europe. I have always liked this mgmt and I feel they handled this primarily negative release well and I appreciate their transparency and guidance on how they plan to fix the issues. But what does this mean for a company that has struggled for the last 5 months, are we now looking at another year plus of lowered guidance, less or no acquisitions, restructuring, and beaten down share price? Thanks
Q: Hi 5i team,
Your comments please on the preliminary unaudited results for Q4 & full year 2018. Would this news change in any way your confidence in the company?
Thanks!
Silvia
Your comments please on the preliminary unaudited results for Q4 & full year 2018. Would this news change in any way your confidence in the company?
Thanks!
Silvia
Q: Knight has been in my portfolio for two years, I've been buying on the dips with an average cost of 7.80$. Should I remain patient or move on. Lots of opportunity out there. Please recommend some alternatives that I may consider should I decide to sell.
Q: Simple question
Does 5i view this deal as significant in any way (from the Globe)
Knight Therapeutics Inc. (GUD-T) announced the closing of a strategic financing agreement in Moksha8 Inc., a specialty pharmaceutical company focused on licensing and marketing “innovative and established therapeutics” in Latin America, for up to US$125-million.
Under the agreement, Knight will initially lend Moksha8 up to US$25-million in working capital funding, of which US$10-million will be issued at closing. Knight said it may issue up to an additional US$100-million in funding for M&A and the acquisition of new licenses.
Does 5i view this deal as significant in any way (from the Globe)
Knight Therapeutics Inc. (GUD-T) announced the closing of a strategic financing agreement in Moksha8 Inc., a specialty pharmaceutical company focused on licensing and marketing “innovative and established therapeutics” in Latin America, for up to US$125-million.
Under the agreement, Knight will initially lend Moksha8 up to US$25-million in working capital funding, of which US$10-million will be issued at closing. Knight said it may issue up to an additional US$100-million in funding for M&A and the acquisition of new licenses.
Q: Good morning,
News on RHT? Do they report at the end of the month?
KC
News on RHT? Do they report at the end of the month?
KC
Q: Could you give your analysis of SUPN. Is it a buy now? Thanks
Q: Hello team,
What is wrong with FDA wanting to review CorMedix's "full data set including secondary endpoints from the LOCK-IT-100 study to facilitate FDA's consideration of CorMedix's request to file the New Drug Application (NDA) for Neutrolin on the basis of the LOCK-IT-100 study results."
Why the 27% drop after the meeting with FDA and willingness of the company to provide the data and fully cooperate?
Hold, Sell, or Average down on CRMD?
Thanks as always.
What is wrong with FDA wanting to review CorMedix's "full data set including secondary endpoints from the LOCK-IT-100 study to facilitate FDA's consideration of CorMedix's request to file the New Drug Application (NDA) for Neutrolin on the basis of the LOCK-IT-100 study results."
Why the 27% drop after the meeting with FDA and willingness of the company to provide the data and fully cooperate?
Hold, Sell, or Average down on CRMD?
Thanks as always.
Q: would appreciate your comments for: Kinross and Prometic
ed
ed
Q: First I want to just thank-you for making me a better investor not just with your recommendations but with your approach. Covalon has. in Appendix B of their annual statement included the notice of the change of auditors. The 'resignation' of BDO is, as it turns out, at the request of Covalon. We are also informed (elsewhere) that there will be no vote on the financial statement. I have gone through about as many of their recent Sedar filings as I can take and perhaps I am reaching here, but is this normal practice to you? Any red flags?
Q: Hello Team,
Would you prefer Pfizer or Merck in this space and why, or would you have a company you would recommend ahead of either.
Thank You,
Barry
Would you prefer Pfizer or Merck in this space and why, or would you have a company you would recommend ahead of either.
Thank You,
Barry
- Medtronic plc. (MDT)
- Stryker Corporation (SYK)
- Thermo Fisher Scientific Inc (TMO)
- Zimmer Biomet Holdings Inc. (ZBH)
Q: Hi 5i,
looking for health care related stocks (other than Drug companies) that pay a dividend and are good for a 10 yr hold. Please rank them in order of reference.
Thanks,
Earl
looking for health care related stocks (other than Drug companies) that pay a dividend and are good for a 10 yr hold. Please rank them in order of reference.
Thanks,
Earl
Q: Hi guys,
What do you think.of SIA as a long term hold or would you prefer Chartwell or maybe a U.S. type company instead.
Thank You.
John.
What do you think.of SIA as a long term hold or would you prefer Chartwell or maybe a U.S. type company instead.
Thank You.
John.
Q: Can I please get your thoughts on this company. I see that the founder of TIO Networks is prominently involved so it caught my attention.
Thanks,
Thanks,
Q: Hello,
I've noticed that you have been recommending Gilead recently as a value pick in the US. I'm a long term (suffering) holder of this one. What is your thesis on why you are recommending it?
I've noticed that you have been recommending Gilead recently as a value pick in the US. I'm a long term (suffering) holder of this one. What is your thesis on why you are recommending it?
Q: This small bio pharmaceutical company is listed in the US. It is working on alternative to opioids drugs. Would appreciate your comments on the future of this company.
Thanks
Thanks
Q: I mainly follow the balanced portfolio I'm looking to add a industrial and a healthcare stock. I have a full position in NFI, CAE and MG. I have full positions in SIS(I have considered it a healthcare company rather than a industrial) and UNH(in the US). I also have a tiny position in COV and a small 2% position in GUD. Would you have more confidence in WSP or TFII? What other healthcare stock would you add? I'm not a high risk investor but understand all stocks have a risk. I have 10+ years. Thank you for your advice I have gained many investment insights.
Q: What are your thoughts on this company. Public for about a year, new drug recently received US and Cdn. Approvals, price reacted well.
Q: What is your take on PLI?? At current prices has this become another risky, penny stock or is there some upside over the next year or two. Does it have any future potential for capital gain?? Thanks for your thoughts